NEWS

Press Releases AND Media
In the News

Attralus Raises $25M in Series A Financing

finsmes.com
Source Author:

September 14, 2020
PDF Version
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

Attralus, a South San Francisco, CA-based biopharmaceutical company focused on creating medicines for systemic amyloidosis, raised $25m in Series A financing.

The round was led by venBio Partners.

The company intends to use the funds to further validate their pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.

Attralus, a South San Francisco, CA-based biopharmaceutical company focused on creating medicines for systemic amyloidosis, raised $25m in Series A financing.

The round was led by venBio Partners.

The company intends to use the funds to further validate their pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.

<< Back to All News

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.